Latest / Peptides Weekly / Ep 3: Nail detachment was over four times more common in people using GLP-1 drugs.

Transcript

Ep 3: Nail detachment was over four times more common in people using GLP-1 drugs. · Peptides Weekly

• 0:00
  Nail detachment was over four times more common in people using glp-1 drugs. This is Peptides Weekly Episode 3. Education and evidence. Never dosing advice. Medical Express carried that report on September 30th. It calls the work the first controlled study of the comparison. A controlled human study can show a gap between groups. It does not tell you why one person's nail lifted. These are Peptide medicines listeners already hear about, so a harm signal sits
• 0:29
  its beside the glucose and weight claims.
• 0:32
  In a new trial result, rather than another pass at weight loss
• 0:35
  totals, Reuters says a Regeneron drug
• 0:38
  halved muscle loss when it was combined
• 0:40
  with Novo's semi-glutide.
• 0:43
  That finding is from a human trial reported September 30.
• 0:47
  Medical Express names the drug Trivogramab
• 0:50
  and calls it anti-myostatin, meaning it blocks myostatin.
• 0:55
  The same report says lean mass can be preserved
• 0:57
  during semi-glutide weight loss and after it.
• 1:01
  Muscle loss and scale weight are different measurements.
• 1:04
  Nothing in these reports states an approval for Travogramab.
• 1:08
  After earlier work on blood vessel markers, nature medicine put a randomized trial online
• 1:13
  on October 1st.
• 1:15
  The people in it had type 2 diabetes.
• 1:17
  The question was how semi-glutide might protect the kidney.
• 1:21
  The notice names histology, multi-parametric MRI, and transcriptomics.
• 1:26
  That is a randomized human mechanism study.
• 1:29
  It is not, on this notice, account of who reached kidney failure.
• 1:34
  A path is not the same thing as an outcome.
• 1:37
  The Lancet's post from EASD 2026 says Mauritius is the first country to show diabetes prevalence
• 1:43
  falling over time, and intermediate hyperglycemia falling with it.
• 1:48
  The measure was the oral glucose tolerance test.
• 1:51
  Next, the criteria WHO recommends, which the post calls the objective gold standard.
• 1:57
  More sits in the Lancet Diabetes and Endocrinology.
• 2:01
  This is population surveillance, not a peptide trial, and it does not show that a drug caused
• 2:06
  the drop.
• 2:07
  Eric Topel pointed to a nature paper from PushMeat and colleagues at Google DeepMind.
• 2:13
  They watermark AI-generated proteins and keep the proteins function, so someone can later
• 2:18
  tell where a design came from.
• 2:20
  A Nature News piece runs beside the research article.
• 2:24
  This is a method's paper about designed proteins, not a human medicine trial, and it does
• 2:29
  not show safety or benefit in people.
• 2:32
  Sleep disorders affect more than 70 million people.
• 2:35
  A 2026 review in brain says, and that number is the doorway into this week's spotlight
• 2:41
  on how to read peptide evidence.
• 2:43
  The review is not selling a sleep drug, it is showing a ladder.
• 2:47
  Optogenetics and chemogenetics can control sleep wake switches in animal models, so sleep
• 2:53
  can be pushed around in those animals by hitting a circuit.
• 2:56
  The same review says moving that control into people faces substantial challenges.
• 3:02
  Some principles look conserved across species.
• 3:05
  Circuit layout, the tools we can actually use, and regulatory limits still differ, so human
• 3:11
  work needs its own designs.
• 3:13
  A clean animal switch is not a human result.
• 3:15
  world. Read the rung before you trust the adjective.
• 3:19
  A cell study asks whether a pathway can fire in a dish. An animal study asks whether
• 3:24
  it matters in a living non-human body under controlled conditions. A small human study
• 3:29
  asks whether a signal shows up in people, often as a biomarker, a scan, or a short safety
• 3:35
  check. An outcome trial asks whether fewer people have the events that change a life. Oregon
• 3:41
  failure, a hospital stay, death, or a score to find in advance.
• 3:46
  Association is not cause.
• 3:48
  A biomarker that moves is not an outcome.
• 3:51
  Stroke research shows the middle rungs are useful and still not final.
• 3:55
  A review in cellular and molecular neurobiology says inflammation and immune processes in
• 4:01
  ischemic stroke were shown in vitro and in animal models, and confirmed in people.
• 4:06
  That is a strong pattern for a methods review.
• 4:09
  view. The same broad process appears on more than one run. The authors still call translation
• 4:14
  into the human disease a hard step, and they say more work has to fill the gaps. Confirming
• 4:20
  a process is not a treatment recipe. A paper on damage associated molecular patterns is
• 4:26
  not a clinic protocol. Animal prediction fails often enough to have its own review. In biochemical
• 4:32
  pharmacology, mechanical and colleagues say animal models have long been used for disease
• 4:37
  biology, target finding, and testing new chemical entities in living animals.
• 4:43
  Then they describe the criticism after clinical trials failed on compounds that had looked
• 4:47
  promising before humans.
• 4:50
  The limit they name is prediction of efficacy, safety, and toxicity in people.
• 4:55
  Their practical point stays on the latter.
• 4:58
  Test an idea in more than one disease model.
• 5:00
  Measure pharmacokinetics and pharmacodynamics and build validated biomarkers earlier so
• 5:06
  you know the target was engaged. The predictive value of an animal model is only as useful
• 5:12
  as the context you read it in. That is the sentence to hold when an ad says,
• 5:17
  shown in animals. Biomarkers need the same caution. A 2026 review in lab animal written about tuberculosis
• 5:25
  markers across species defines a biomarker as a measurable indicator of a biological state.
• 5:31
  Those indicators can help diagnosis, prognosis, and watching a treatment.
• 5:36
  Clinical studies are limited by cost, ethics, and what you can sample, which is why models
• 5:41
  exist.
• 5:42
  Species differences are both the advantage and the limit.
• 5:46
  The review's conclusion is that animal data and human data have to be read together.
• 5:51
  A marker that moves in a model is a candidate.
• 5:54
  It is not yet a diagnosis in a person.
• 5:56
  mechanism work can be precise and still sit below outcomes.
• 6:00
  A pharmacotherapy review of vanqulemice and kidney injury describes pre-clinical models
• 6:06
  in which the drug builds up in proximal tubule cells, oxidative stress follows, and cells
• 6:11
  die by apoptosis.
• 6:13
  Injury in those models tracks more with high peak concentrations and the area under the
• 6:18
  curve than with trough levels.
• 6:21
  That is mechanism, mostly pre-clinical.
• 6:23
  The review also says ordinary clinical use still has a poor map of what drives the injury,
• 6:29
  and several gaps remain before the drug could be made less toxic.
• 6:33
  This spotlight is about seeing that gap, not about vancomycin care.
• 6:38
  What is not established is any universal exchange rate from one rung to the next.
• 6:43
  The sleep review does not say a conserved circuit guarantees a human benefit.
• 6:47
  it. The stroke review does not say human confirmation of inflammation has closed the gap. The animal
• 6:53
  model review does not say better biomarkers will save every failed prediction. None of these papers
• 6:59
  is a peptide outcome trial, and none of them ranks a named peptide medicine. This is not a compound,
• 7:06
  so it has no approval, no label, and no authorized indication. The risk is misreading. A cell result
• 7:13
  treated as an animal result, an animal result treated as a human result, or a bio-marker
• 7:18
  shift treated as a clinical outcome. Unregulated products add a problem the method cannot fix.
• 7:25
  A study of a pure research peptide does not describe the vial in a gray market ad.
• 7:30
  Four questions cover most claims. What was studied, in what kind of system, what was measured,
• 7:36
  and was that measurement the outcome a person would actually care about?
• 7:40
  One thing worth knowing is that a controlled human comparison can flag a nail change in
• 7:45
  GLP1 users without proving the cause in any one person.
• 7:49
  A human trial that follows lean mass is measuring something a bathroom scale does not, so weight
• 7:55
  change and muscle change are separate facts.
• 7:58
  A randomized mechanism study in Type 2 diabetes can show how semi-glutide meets kidney tissue
• 8:03
  and still not count kidney failure outcomes.
• 8:06
  A country-level fall in diabetes prevalence, read with glucose tolerance testing, is surveillance
• 8:12
  of a population, not a verdict on a peptide.
• 8:16
  That's peptides weekly.
• 8:18
  This show is education, not medical advice.
• 8:21
  Talk to your own clinician before acting on anything you heard.
• 8:24
  I'm Patrick in Vancouver.
• 8:26
  See you next week.
• 8:27
  One more thing.
• 8:29
  If you liked today's episode, our sister show Models and Agents is worth a spot in your
• 8:33
  feed.
• 8:34
  You're daily briefing on AI models and agents.
• 8:37
  It's one of the Narra Network's daily briefings, all free at NarraNetwork.com.
• 8:43
  Prefer reading?
• 8:44
  Today's full write-up, sources, and transcript are on the episode blog at NarraNetwork.com.
• 8:50
  Same briefing, readable format.
• 8:52
  This episode used AI voice synthesis of my voice.
• 8:56
  Editorial selection and analysis are my own.